What other chemotherapy would you consider in a patient with high-risk node positive ER+, HER2- disease that developed pulmonary toxicity to paclitaxel and refuses any more taxanes?

This is certainly a tough situation, but one that comes up when we cannot complete what we think is sufficient adjuvant therapy with the taxane portion of the adjuvant chemotherapy regimen, AC-weekly Taxol. In most cases, we would consider an alternate taxane, but not in this case because the patien...